中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
18期
3252-3256
,共5页
顾岩%李国华%高俊珍%郭丽萍%乔晓娟%贺岚%王美玲%闫丽%付秀华
顧巖%李國華%高俊珍%郭麗萍%喬曉娟%賀嵐%王美玲%閆麗%付秀華
고암%리국화%고준진%곽려평%교효연%하람%왕미령%염려%부수화
癌,非小细胞肺%多药耐药相关蛋白质类%DNA拓扑异构酶类,Ⅱ型
癌,非小細胞肺%多藥耐藥相關蛋白質類%DNA拓撲異構酶類,Ⅱ型
암,비소세포폐%다약내약상관단백질류%DNA탁복이구매류,Ⅱ형
Carcinoma,non-small-cell lung%Multidrug resistance-associated proteins%DNA Topoisomerases,type Ⅱ
目的：探讨MRP1、ToPo-Ⅱ在非小细胞肺癌（NSCLC）中的表达及其临床意义。方法采用免疫组织化学法检测117例NSCLC，26例对照组断端支气管黏膜中MRP1、ToP o-Ⅱ的表达水平。结果（1）MRP1在NSCLC阳性表达高于对照组（P＜0.05），与组织类型、分期、淋巴结转移有关（P＜0.05）；MRP1在鳞癌中的表达低于腺癌（P＜0.05）；随分期增高，淋巴结转移表达增强；MRP1表达与性别、年龄、分化无关（P＞0.05）。（2）ToP o-Ⅱ表达在NSCLC组高于对照组（P＜0.05）；与组织类型、分化有关（P＜0.05）；鳞癌ToP o-Ⅱ表达高于腺癌；随分化程度降低表达增强（P＜0.05）；ToP o-Ⅱ与性别、年龄、分期、淋巴结转移无关（P＞0.05）。（3）MRP1与ToP o-Ⅱ呈负相关（r=-0.269，P＜0.05）。结论 NSCLC存在MRP1及ToP o-Ⅱ的高表达，两者可能参与肿瘤进展。
目的：探討MRP1、ToPo-Ⅱ在非小細胞肺癌（NSCLC）中的錶達及其臨床意義。方法採用免疫組織化學法檢測117例NSCLC，26例對照組斷耑支氣管黏膜中MRP1、ToP o-Ⅱ的錶達水平。結果（1）MRP1在NSCLC暘性錶達高于對照組（P＜0.05），與組織類型、分期、淋巴結轉移有關（P＜0.05）；MRP1在鱗癌中的錶達低于腺癌（P＜0.05）；隨分期增高，淋巴結轉移錶達增彊；MRP1錶達與性彆、年齡、分化無關（P＞0.05）。（2）ToP o-Ⅱ錶達在NSCLC組高于對照組（P＜0.05）；與組織類型、分化有關（P＜0.05）；鱗癌ToP o-Ⅱ錶達高于腺癌；隨分化程度降低錶達增彊（P＜0.05）；ToP o-Ⅱ與性彆、年齡、分期、淋巴結轉移無關（P＞0.05）。（3）MRP1與ToP o-Ⅱ呈負相關（r=-0.269，P＜0.05）。結論 NSCLC存在MRP1及ToP o-Ⅱ的高錶達，兩者可能參與腫瘤進展。
목적：탐토MRP1、ToPo-Ⅱ재비소세포폐암（NSCLC）중적표체급기림상의의。방법채용면역조직화학법검측117례NSCLC，26례대조조단단지기관점막중MRP1、ToP o-Ⅱ적표체수평。결과（1）MRP1재NSCLC양성표체고우대조조（P＜0.05），여조직류형、분기、림파결전이유관（P＜0.05）；MRP1재린암중적표체저우선암（P＜0.05）；수분기증고，림파결전이표체증강；MRP1표체여성별、년령、분화무관（P＞0.05）。（2）ToP o-Ⅱ표체재NSCLC조고우대조조（P＜0.05）；여조직류형、분화유관（P＜0.05）；린암ToP o-Ⅱ표체고우선암；수분화정도강저표체증강（P＜0.05）；ToP o-Ⅱ여성별、년령、분기、림파결전이무관（P＞0.05）。（3）MRP1여ToP o-Ⅱ정부상관（r=-0.269，P＜0.05）。결론 NSCLC존재MRP1급ToP o-Ⅱ적고표체，량자가능삼여종류진전。
Objective To investigate the expression and clinical significance of multidrug resistance associated protein-1 and DNA topoisomerase-Ⅱ. Methods MRP1 and ToPo-Ⅱ were measured in 117 samples of non-small cell lung cancer tissues by immunohistochemistry two-step method using monoclonal antibody to their protein. Results The positive expression of MRP1 was higher than that in sectional bronchial mucosa (P<0.05);MRP1 expression in adenocarcinoma (Ad) was significantly higher than that in squamous carcinoma (P<0.05); The positive expression of MRP1 in Ⅲ stage group was higher than that in I stage group (P<0.05);MRP1 expression correlated significantly with lymph node metastasis; But the positive rate of the expression of MRP1 had no significantly different between the different degrees of cell differentiation (P>0.05). The positive rate of ToPo-Ⅱ was significantly higher in the group of the squamous cell carcinomas than that in that of the adenocarcinoma (P<0.05); ToP o-Ⅱexpression in the poorly differentiated group was higher than one in highly differentiated group; The positive rates of ToPo-Ⅱ was not correlated with TMN stage and lymph node metastasis. ToPo-Ⅱexpression correlated with MRP1(r=-0.269, P<0.05). Conclusion The coexpression of MRP1 and ToPo-Ⅱ could be involved in the advanced NSCLC .
